Citadel Advisors
AUGX

Citadel Advisors’s Augmedix, Inc. Common Stock AUGX Stock Holding History

Citadel Advisors’s Portfolio AUGX Stock Details AUGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,000
Closed -$4.4K – 15538
2024
Q2 		$4.4K Sell
5,000
-100
-2% -$206 ﹤0.01% 13488
2024
Q1 		$20.9K Buy
5,100
+3,400
+200% +$15.2K ﹤0.01% 12990
2023
Q4 		$9.95K Sell
1,700
-900
-35% -$4.74K ﹤0.01% 13131
2023
Q3 		$13.4K Buy
2,600
+2,500
+2,500% +$11.7K ﹤0.01% 12927
2023
Q2 		$481 Buy
+100
New +$346 ﹤0.01% 14103

Other funds holding AUGX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
SM
Samjo Management New York $231M AUM 13.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Citadel Advisors's AUGX Position: Q3 2024 in Review

Citadel Advisors sold out of Augmedix, Inc. Common Stock (AUGX) in Q3 2024, closing a stake of 1,850,000 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in AUGX in Q4 2021 and held it in 8 quarters. The position peaked at $7.73M in Q1 2024. 45 funds tracked by Wall St. Rank hold AUGX as of Q3 2024.

  • Citadel Advisors reported no remaining Augmedix, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 1,850,000 Augmedix, Inc. Common Stock shares in Q3 2024, an estimated $1.63M.
  • Citadel Advisors first reported a position in Augmedix, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • Citadel Advisors's Augmedix, Inc. Common Stock position peaked at $7.73M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.